How Pinotbio Is Helping Build Korea's ADC Ecosystem

'Imbalance' In Technology Demand/Supply

Pinotbio CEO Dooyoung Jung shares his views on the Korean ADC industry’s situation and efforts needed for the sector to grow, the strengths of his company's camptothecin-based platform and pipeline, and R&D and business strategies.

evolution
Pinotbio Aims To Become Mainstream Next Generation ADC Player • Source: Shutterstock

Antibody-drug conjugate (ADC) technology is poised to remain under the spotlight and become a main global trend that will lead anticancer drug development in the next several years.

In South Korea, meanwhile, ADC players are trying to build an ecosystem amid an “imbalance” in the demand and supply...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

More from Focus On Asia

Torrent Acquires JB Chem In 2025’s Biggest Deal For Indian Pharma

 
• By 

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By 

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut